Role of chemokines in resectable non-small cell lung cancer (NSCLC)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F19%3AN0000122" target="_blank" >RIV/00064190:_____/19:N0000122 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.annalsofoncology.org/article/S0923-7534(19)30224-8/fulltext" target="_blank" >https://www.annalsofoncology.org/article/S0923-7534(19)30224-8/fulltext</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/annonc/mdz072.007" target="_blank" >10.1093/annonc/mdz072.007</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Role of chemokines in resectable non-small cell lung cancer (NSCLC)

Popis výsledku v původním jazyce

Background: Complex network of chemokines is a part of immune reaction targeted against tumor cells. Chemokines influence cancer growth. It is not clear whether the concentrations of chemokines at the time of diagnosis of NSCLC reflect extent of the disease. Aim: To compare chemokine concentrations (CCL2, CCL8, CXCL12) in plasma of patients with resectable NSCLC to those without cancer. To find out whether the chemokine concentrations differ according to stage of the disease. Methods: We enrolled 69 patients undergoing surgery for proven/suspected NSCLC (37 males- mean age 66 years, 32 females- mean age 64 years). They underwent standard diagnostic and staging procedure to determine resectability (CT/PET-CT, bronchoscopy, ev. abdominal ultrasound), then surgery was made. We diagnosed 42 patients with NSCLC, 27 patients in the control group had benign lung pathologies (e.g. chondrohamatoma, fibrous tissue) and remained as the control group. We took plasma samples before surgery in treatment naive patients. The chemokine concentrations were assesed by ELISA LSBio Kits. The results were stated in pg/ml (CCL2, CCL8), ng/ml (CXCL12). Parametric statistics was used for results analysis. Conclusions: Chemokine values did not differ in NSCLC versus control group. Patients with NSCLC stages II and IIIA had significantly higher CXCL12 concentrations than control group. This could be because CXCL12 promotes tumor growth and metastasis.

Název v anglickém jazyce

Role of chemokines in resectable non-small cell lung cancer (NSCLC)

Popis výsledku anglicky

Background: Complex network of chemokines is a part of immune reaction targeted against tumor cells. Chemokines influence cancer growth. It is not clear whether the concentrations of chemokines at the time of diagnosis of NSCLC reflect extent of the disease. Aim: To compare chemokine concentrations (CCL2, CCL8, CXCL12) in plasma of patients with resectable NSCLC to those without cancer. To find out whether the chemokine concentrations differ according to stage of the disease. Methods: We enrolled 69 patients undergoing surgery for proven/suspected NSCLC (37 males- mean age 66 years, 32 females- mean age 64 years). They underwent standard diagnostic and staging procedure to determine resectability (CT/PET-CT, bronchoscopy, ev. abdominal ultrasound), then surgery was made. We diagnosed 42 patients with NSCLC, 27 patients in the control group had benign lung pathologies (e.g. chondrohamatoma, fibrous tissue) and remained as the control group. We took plasma samples before surgery in treatment naive patients. The chemokine concentrations were assesed by ELISA LSBio Kits. The results were stated in pg/ml (CCL2, CCL8), ng/ml (CXCL12). Parametric statistics was used for results analysis. Conclusions: Chemokine values did not differ in NSCLC versus control group. Patients with NSCLC stages II and IIIA had significantly higher CXCL12 concentrations than control group. This could be because CXCL12 promotes tumor growth and metastasis.

Druh

J_ost - Ostatní články v recenzovaných periodicích

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of oncology : official journal of the European Society for Medical Oncology

ISSN

0923-7534

e-ISSN

1569-8041

Svazek periodika

neuveden

Číslo periodika v rámci svazku

04/2019

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

1

Strana od-do

Suppl 2:ii3

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—